Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 96 (3), 111-7

Xenotransplantation: Where Are We Today?

Affiliations
Review

Xenotransplantation: Where Are We Today?

M D Dooldeniya et al. J R Soc Med.

Figures

<i>Figure 1</i>
Figure 1
Numbers of cadaveric donors and transplants in the UK and Republic of Ireland, 1991-2000 and patients on the waiting list at 31 December. Statistics prepared by UK Transplant from the National Transplant Database maintained on behalf of transplant services in the UK and Republic of Ireland [www.uktransplant.nhs.uk] (Reproduced by permission)
<i>Figure 2</i>
Figure 2
Direct xenorecognition. Xenogeneic APC presents peptide to the recipient CD4+ T cell via the xenogeneic MHC class II molecules. This results in the production of interleukin 2 (IL-2) by the CD4+ T cell. IL-2 acts on the CD8+ T cell which itself recognizes xenogeneic peptide presented via the MHC class I on the xenogeneic APC
<i>Figure 3</i>
Figure 3
Indirect xenorecognition. Shed antigens from the xenogeneic cell are taken up by the responder antigen presenting cell (APC) to be presented to the CD4+ T cell via MHC class II molecule, which results in generation of the effector mechanism

Similar articles

See all similar articles

Cited by 9 articles

See all "Cited by" articles
Feedback